Clinical trials
Phase 2 Postoperative Complications trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Unknown status | 5 |
| Recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assiut University | 1 |
| Buddhist Tzu Chi General Hospital | 1 |
| Cairo University | 1 |
| Chengdu University of Traditional Chinese Medicine | 1 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 1 |
| Fundacion Clinica Valle del Lili | 1 |
| Gynecologic Oncology Group | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| Inotek Pharmaceuticals Corporation | 1 |
| Institute of Cancer Research, United Kingdom | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Postoperative Complications | 27 |
| Lymphedema | 2 |
| Postoperative Pain | 2 |
| Acute Lung Injury | 1 |
| Agnosia | 1 |
| Appendiceal Neoplasms | 1 |
| Blood Loss, Surgical | 1 |
| Breast Neoplasms | 1 |
| COVID-19 | 1 |
| Cecal Neoplasms | 1 |
Trials
Showing 26 to 27 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.